AR052079A1 - Dispersion solida estable de un derivado de alcaloide de la vinca y proceso para elaborarla - Google Patents

Dispersion solida estable de un derivado de alcaloide de la vinca y proceso para elaborarla

Info

Publication number
AR052079A1
AR052079A1 ARP050105628A ARP050105628A AR052079A1 AR 052079 A1 AR052079 A1 AR 052079A1 AR P050105628 A ARP050105628 A AR P050105628A AR P050105628 A ARP050105628 A AR P050105628A AR 052079 A1 AR052079 A1 AR 052079A1
Authority
AR
Argentina
Prior art keywords
vinca
derivative
dispersion
polyethylene glycol
water
Prior art date
Application number
ARP050105628A
Other languages
English (en)
Original Assignee
Pf Medicament
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US11/025,348 external-priority patent/US20060147518A1/en
Priority claimed from FR0414069A external-priority patent/FR2880274B1/fr
Application filed by Pf Medicament filed Critical Pf Medicament
Publication of AR052079A1 publication Critical patent/AR052079A1/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/10Dispersions; Emulsions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/28Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2886Dragees; Coated pills or tablets, e.g. with film or compression coating having two or more different drug-free coatings; Tablets of the type inert core-drug layer-inactive layer
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4808Preparations in capsules, e.g. of gelatin, of chocolate characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2013Organic compounds, e.g. phospholipids, fats
    • A61K9/2018Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/28Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806Coating materials
    • A61K9/2833Organic macromolecular compounds
    • A61K9/284Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A61K9/2846Poly(meth)acrylates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/28Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806Coating materials
    • A61K9/2833Organic macromolecular compounds
    • A61K9/286Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Dispersion Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Cosmetics (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

Dispersiones solidas y estables de un derivado hidrosoluble de alcaloides de la vinca como por ejemplo la vinorelbina di tartrato en por lo menos un polietilenglicol, con una masa molecular de entre 800 y 30.000. Reivindicacion 11: Un proceso para la elaboracion de una composicion farmacéutica para la administracion oral e derivados hidrosolubles de alcaloides de la vinca en forma de dispersion solida, de acuerdo con una de las reivindicaciones 1 a 10, que se caracteriza por el hecho de que se llevan a cabo la siguientes operaciones: se calienta el polietilenglicol a una temperatura ligeramente superior a su temperatura de fusion a fin de llevarlo al estado líquido y se mezcla el derivado hidrosoluble de alcaloide de la vinca en forma de polvo, con agitacion, con el polietilenglicol obtenido en el paso anterior, a fin de formar una dispersion y se enfría dicha dispersion para llevarla al estado solido.
ARP050105628A 2004-12-30 2005-12-29 Dispersion solida estable de un derivado de alcaloide de la vinca y proceso para elaborarla AR052079A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US11/025,348 US20060147518A1 (en) 2004-12-30 2004-12-30 Stable solid dispersion of a derivative of vinca alkaloid and process for manufacturing it
FR0414069A FR2880274B1 (fr) 2004-12-30 2004-12-30 Dispersion solide stable d'un derive d'alcaloides de vinca et son procede de fabrication

Publications (1)

Publication Number Publication Date
AR052079A1 true AR052079A1 (es) 2007-02-28

Family

ID=36046982

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP050105628A AR052079A1 (es) 2004-12-30 2005-12-29 Dispersion solida estable de un derivado de alcaloide de la vinca y proceso para elaborarla

Country Status (22)

Country Link
US (1) US9061015B2 (es)
EP (1) EP1830817B1 (es)
JP (1) JP5256739B2 (es)
KR (1) KR101320408B1 (es)
AR (1) AR052079A1 (es)
AU (1) AU2005321346B2 (es)
BR (1) BRPI0519466B8 (es)
CA (1) CA2591056C (es)
CY (1) CY1113868T1 (es)
DK (1) DK1830817T3 (es)
ES (1) ES2401992T3 (es)
HR (1) HRP20130276T1 (es)
IL (1) IL184095A (es)
MX (1) MX2007008059A (es)
NZ (1) NZ554793A (es)
PL (1) PL1830817T3 (es)
PT (1) PT1830817E (es)
RS (1) RS52697B (es)
RU (1) RU2412687C2 (es)
SI (1) SI1830817T1 (es)
TW (1) TWI419714B (es)
WO (1) WO2006069938A1 (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1989212B1 (en) * 2006-02-17 2013-06-19 Cascade Prodrug Inc. Treatment of hyperproliferative diseases with vinca alkaloid n-oxide and analogs
AU2008214199A1 (en) * 2007-02-09 2008-08-14 Poniard Pharmaceuticals, Inc. Encapsulated picoplatin
FR2918566B1 (fr) 2007-07-11 2009-10-09 Pierre Fabre Medicament Sa Composition pharmaceutique stable d'un sel hydrosoluble de vinflunine.
FR2918567B1 (fr) * 2007-07-11 2012-08-03 Pf Medicament Composition pharmaceutique stable d'un sel hydrosoluble de vinorelbine.
RU2730521C2 (ru) 2016-03-09 2020-08-24 Синбиас Фарма АГ Винорелбина монотартрат и его фармацевтическое применение

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6811088B2 (en) * 1993-05-28 2004-11-02 Symbol Technologies, Inc. Portable data collection system
HN1998000115A (es) * 1997-08-21 1999-06-02 Warner Lambert Co Formas de dosificación farmacéuticas sólidas
NL1009780C2 (nl) 1998-07-31 2000-02-01 Peter Hubertus Elisabeth Van D Plantpot.
DE10000792A1 (de) * 2000-01-11 2001-07-19 Bernhard C Lippold Formulierungen von Wirkstoffen in Form einer festen Dispersion
US20020004070A1 (en) * 2000-02-24 2002-01-10 Rudnic Edward M. Antineoplastic product, use and formulation thereof
EP1289560A1 (en) * 2000-06-12 2003-03-12 SmithKline Beecham Corporation Novel solid dispersion compositions
IT1320176B1 (it) * 2000-12-22 2003-11-26 Nicox Sa Dispersioni solide di principi attivi nitrati.
US20030212102A1 (en) * 2001-06-12 2003-11-13 Koretke Todd W Novel solid dispersion compositions
EP1530459B1 (en) * 2002-05-31 2010-03-31 R.P. Scherer Technologies, LLC Oral pharmaceutical composition for soft capsules containing vinorelbine and method of treatment
US20050048119A1 (en) * 2002-09-20 2005-03-03 Avinash Nangia Controlled release composition with semi-permeable membrane and poloxamer flux enhancer

Also Published As

Publication number Publication date
HRP20130276T1 (hr) 2013-04-30
KR101320408B1 (ko) 2013-10-30
DK1830817T3 (da) 2013-04-02
IL184095A (en) 2015-08-31
AU2005321346B2 (en) 2011-06-23
PT1830817E (pt) 2013-04-01
BRPI0519466B1 (pt) 2020-10-20
RU2412687C2 (ru) 2011-02-27
NZ554793A (en) 2010-04-30
WO2006069938A1 (en) 2006-07-06
JP5256739B2 (ja) 2013-08-07
PL1830817T3 (pl) 2013-06-28
US20080089935A1 (en) 2008-04-17
KR20070094598A (ko) 2007-09-20
CA2591056A1 (en) 2006-07-06
TW200635619A (en) 2006-10-16
CY1113868T1 (el) 2016-07-27
US9061015B2 (en) 2015-06-23
BRPI0519466A2 (pt) 2009-02-03
BRPI0519466B8 (pt) 2021-05-25
RS52697B (en) 2013-08-30
JP2008526711A (ja) 2008-07-24
TWI419714B (zh) 2013-12-21
ES2401992T3 (es) 2013-04-26
SI1830817T1 (sl) 2013-04-30
EP1830817B1 (en) 2013-01-02
RU2007124572A (ru) 2009-01-10
AU2005321346A8 (en) 2011-10-13
AU2005321346A1 (en) 2006-07-06
CA2591056C (en) 2013-11-12
MX2007008059A (es) 2007-07-17
EP1830817A1 (en) 2007-09-12
IL184095A0 (en) 2007-10-31

Similar Documents

Publication Publication Date Title
AR052079A1 (es) Dispersion solida estable de un derivado de alcaloide de la vinca y proceso para elaborarla
CY1116554T1 (el) Αλατα κλοπιδογρελης και μεθοδος παρασκευης
ES2551860T3 (es) Forma de dosificación farmacéutica para administración oral de un inhibidor de la familia de Bcl-2
EA202090659A1 (ru) СОСТАВЫ, СОДЕРЖАЩИЕ 6-(2-ГИДРОКСИ-2-МЕТИЛПРОПОКСИ)-4-(6-(6-((6-МЕТОКСИПИРИДИН-3-ИЛ)МЕТИЛ)-3,6-ДИАЗАБИЦИКЛО[3.1.1]ГЕПТАН-3-ИЛ)ПИРИДИН-3-ИЛ)ПИРАЗОЛО[1,5-a]ПИРИДИН-3-КАРБОНИТРИЛ
HRP20050676B1 (hr) Tekuä†i farmaceutski oblici palonosetrona
TW200640502A (en) Tablets with improved drug substance dispersibility
AR084067A1 (es) Composiciones farmaceuticas
NO20081325L (no) Nye doseringsformuleringer
ATE470443T1 (de) Indol-1-yl-essigsäurederivate
TNSN08543A1 (en) Pharmaceutical composition containing a tetrahydrofolic acid
EP1312366A8 (en) Aqueous pharmaceutical compositions
WO2006070325A3 (en) 2,3,4,9-tetrahydro-1h-carbazole derivatives as crth2 receptor antagonists
US7919126B2 (en) Effervescent composition and method of making an effervescent composition including a viscous component
TN2009000362A1 (en) Weekly administration of dipeptidyl peptidase inhibitors
CA2535013A1 (en) Micro-particle fatty acid salt solid dosage formulations for therapeutic agents
AR038947A1 (es) Suspension oral de sabor agradable y metodo
WO2006008512A3 (en) Anti-histaminic composition
CN103239427A (zh) 一种口腔内分散溶解的膜剂
JPS5883634A (ja) 経口投与用の新規な固体生薬形態及びその製造方法
JP2008518909A (ja) 非水性極性溶媒中の10−ヒドロキシカンプトテシン化合物の溶解度を増加させるための薬剤製剤
JP5544671B1 (ja) 一剤型皮膚外用剤
Yu et al. Preparation and characterization of piroxicam/poloxamer solid dispersion prepared by melting method and solvent method
PE20091015A1 (es) Combinacion anti-retroviral novedosa
JPS60109519A (ja) ニフェジピン坐剤
EP1492538A1 (en) Meloxicam suppositories containing e.g. polyethylenglycol

Legal Events

Date Code Title Description
FB Suspension of granting procedure